新光药业(300519) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥75,760,839.16, reflecting a year-on-year growth of 3.89%[7] - Net profit attributable to shareholders was ¥26,054,265.33, up 5.84% from the same period last year[7] - The net profit after deducting non-recurring gains and losses was ¥25,465,017.14, representing a significant increase of 13.37% year-on-year[7] - Basic earnings per share for the reporting period was ¥0.1628, an increase of 5.78% compared to the same period last year[7] - Year-to-date total operating revenue was CNY 213,143,239.39, a rise of 4.67% from CNY 204,001,563.41 in the same period last year[36] - Year-to-date net profit amounted to CNY 69,251,237.85, an increase of 4.57% compared to CNY 66,236,515.29 in the previous year[37] - The net profit attributable to the parent company for Q3 2019 was CNY 69,251,237.85, an increase from CNY 66,236,515.29 in Q3 2018, representing a growth of approximately 3.06%[38] - The total comprehensive income attributable to the parent company for Q3 2019 was CNY 69,173,879.31, compared to CNY 65,836,731.96 in the same period last year, indicating an increase of about 3.12%[38] Assets and Liabilities - Total assets at the end of the reporting period reached ¥839,451,373.77, an increase of 2.06% compared to the end of the previous year[7] - Total assets increased to 839,451,373.77 from 822,499,972.11, reflecting overall growth in the company's financial position[28] - The company's total assets and equity as of the end of Q3 2019 were CNY 839,451,373.77 and CNY 774,433,941.03 respectively, indicating a solid financial position[30] - Current liabilities totaled ¥58,066,478.92, while non-current liabilities were ¥11,173,431.47, leading to total liabilities of ¥69,239,910.39[47] - Shareholders' equity reached ¥753,260,061.72, with retained earnings of ¥365,450,623.44[48] Cash Flow - Cash flow from operating activities for the year-to-date was ¥65,949,698.46, an increase of 21.37%[7] - Cash flow from operating activities for Q3 2019 was CNY 65,949,698.46, compared to CNY 54,338,653.81 in Q3 2018, marking an increase of about 21.5%[41] - The total cash inflow from operating activities was CNY 205,822,962.15, compared to CNY 192,389,845.16 in Q3 2018, reflecting an increase of about 7%[41] - The total cash outflow from operating activities was CNY 139,873,263.69, slightly up from CNY 138,051,191.35 in Q3 2018, indicating a marginal increase of about 1.3%[41] - Cash and cash equivalents rose to 437,064,244.34 from 406,489,733.56, indicating improved liquidity[27] - The cash and cash equivalents at the end of Q3 2019 stood at CNY 437,064,244.34, an increase from CNY 357,966,577.28 at the end of Q3 2018, representing a growth of approximately 22.1%[42] Shareholder Information - The total number of shareholders at the end of the reporting period was 13,434[11] - The largest shareholder, Wang Yuejun, holds 38.25% of the shares, totaling 61,200,000 shares[11] Financial Changes and Adjustments - Financial expenses decreased by 77.92% to -9,716,882.46 due to increased interest income during the reporting period[18] - Asset impairment losses surged by 6363.06% to 575,395.61, primarily due to changes in accounts receivable balances[18] - Other income increased by 430.97% to 1,344,886.96, mainly from increased government subsidies received[18] - Investment income decreased by 47.69% to 2,853,802.53, attributed to reduced returns from financial products[18] - Financial expenses showed a significant change, with a net income of CNY -3,203,757.21 in Q3 2019 compared to CNY -1,436,838.81 in the same period last year[33] - The report indicates a compliance with new financial instrument standards, affecting the classification of equity investments[48] Other Information - The company reported no significant changes in financial data or indicators that would require special explanation[17] - The company has not undergone an audit for the third quarter report[49] - Research and development expenses for Q3 2019 were CNY 4,062,582.27, slightly up from CNY 4,017,460.63 in Q3 2018[33] - The company reported a decrease in other comprehensive income, with a net loss of CNY -297,812.14 in Q3 2019 compared to a gain of CNY 103,628.34 in Q3 2018[34]